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Background
Although several studies have examined the treatment of
mania in routine clinical settings in individual countries,
there has yet to be an observational study of actual care to
evaluate the short and long-term management of patients
with mania across Europe in terms of clinical, functional
and economic outcomes.
EMBLEM (European Mania in Bipolar Evaluation of Med-
ication) is a 2-year prospective observational study on the
outcomes of pharmacological treatment for acute mania
in the context of bipolar disorder. It has been successfully
implemented in 14 European countries since its start in
December 2002. Enrollment into the study ended on June
30, 2004. Follow-up observations will continue until July
2006.
The current objective is to describe the baseline treatment
patterns of 3536 patients enrolled into EMBLEM during
an acute manic episode.
Materials and methods
EMBLEM is a 2-year prospective, Pan-European observa-
tional study on the outcomes of pharmacological treat-
ment for mania in the context of bipolar disorder. Adult
patients are enrolled if they: present within the standard
course of care as in- or outpatient; have, at the discretion
of the treating psychiatrist, initiated or changed oral med-
ication (antipsychotic, lithium or anticonvulsant) for
treatment of acute mania; are not participating in an inter-
ventional study.
Investigators were asked, but not required, to include 50%
of patients into the study who were initiated or changed
to olanzapine and 50% of patients initiated or changed to
non-olanzapine treatment. 530 psychiatrists enrolled
3681 patients in 14 European countries using the same
study methods including assessment of mood with CGI-
BP mania and CGI-BP depression rating scales as well as
the Life Chart Method.
Results
Baseline analysis has been completed with the last patient
having been enrolled in June 2004. We will present base-
line data of 3536 patients including suicide history, treat-
ment patterns prior to and after start of new medication as
well as the reason for start of new oral medication.
Discussion
With 3684 patients having been enrolled, EMBLEM is the
biggest naturalistic study on longitudinal outcomes asso-
ciated with pharmacological treatment of acute mania.
1/4 of the patients had at least once attempted suicide.
1/4 of the patients were not taking any anti-manic medi-
cation when entering into the study.
Lack of effectiveness is the most common reason for
switching oral medication.
Atypicals represented the 69% of the medication (antipsy-
chotics, lithium or anticonvulsants) as monotherapy fol-
lowing the start of new oral medication.
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